Table 1 Baseline characteristics.

	All patients		SII-low patients		SII-high patients		p
	n = 706	(%)	n = 311	(%)	n = 310	(%)
Age-years, median (IQR)	60 (53–67)		60 (53–69)		60 (53–70)		0.710
Sex							0.317
Male	531	75.2	229	73.6	239	77.1
Female	175	24.8	82	26.4	71	22.9
Histological Type							0.196
Clear Cell	563	79.7	241	77.5	257	82.9
Non-clear Cell	94	13.3	46	14.8	36	11.6
Missing	49	6.9	24	7.7	17	5.5
Sarcomatoid Feature							0.830
Yes	83	11.8	35	11.3	39	12.6
No	407	57.6	182	58.5	192	61.9
Missing	216	30.6	94	30.2	79	25.5
Fuhrman Grade							0.076
1–2	124	17.6	63	20.3	43	13.9
3–4	297	42.1	129	41.4	133	42.9
Missing	285	40.4	119	38.3	134	43.2
Previous Nephrectomy							< 0.001
Yes	525	74.4	260	83.6	199	64.2
No	177	25.1	50	16.1	110	35.5
Missing	4	0.6	1	0.3	1	0.3
Systemic Treatment							< 0.001
Sunitinib	404	57.2	197	63.3	152	49.0
Pazopanib	302	42.8	114	36.7	158	51.0
IMDC Risk							< 0.001
Favorable	116	16.4	83	26.7	33	10.6
Intermediate	332	47.0	175	56.3	152	49.0
Poor	128	18.1	25	8.0	98	31.6
Missing	130	18.4	28	9.0	27	8.7
MSKCC Risk							< 0.001
Favorable	91	12.9	64	20.6	27	8.7
Intermediate	279	39.5	148	47.6	128	41.3
High	87	12.3	27	8.7	59	19.0
Missing	249	35.3	72	23.2	96	31.0
Previous Cytokine Use							0.032
Yes	334	47.3	152	48.9	125	40.3
No	372	52.7	159	51.1	185	59.7
Metastatic Sites
Lung	319	51.4	161	51.8	158	51.0	0.886
Bone	259	41.7	100	32.2	159	51.3	< 0.001
Liver	92	14.8	42	13.5	50	16.1	0.252
CNS	58	9.3	18	5.8	40	12.9	0.026
Performance Status							0.002
ECOG 0–1	515	72.9	243	78.1	207	66.8
ECOG 2–3-4	149	21.1	55	17.7	87	28.1
Missing	42	5.9	13	4.2	16	5.2

ECOG eastern cooperative oncology group, IMDC international metastatic renal cell carcinoma database consortium, IQR interquartile range, MSKCC memorial sloan kettering cancer center.
Significant values are in bold.

Quick links

Search